Reports Q4 revenue $5.08B, consensus $5.0B. "2022 was another impressive year for Moderna, with over $19 billion in revenue and significant clinical breakthroughs across our portfolio. We continue to provide our Omicron-targeting bivalent vaccines worldwide, with the latest real-world evidence highlighting the continued protection of our vaccines against hospitalization and death. Our infectious disease platform continues to progress with positive Phase 3 data in RSV for older adults. We are investing to scale Phase 3 manufacturing for personalized cancer vaccines so that we can run several Phase 3 studies simultaneously. With planned R&D investments of $4.5 billion for the year, I am excited about the new medicines we believe we will bring to patients in the coming few years," said Stephane Bancel, CEO.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Moderna Earnings Update: Did it Beat Estimate Forecasts?
- Moderna Falls as Q4 Results Disappoint
- Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940
- Moderna, Life Edit enter collaboration for in vivo gene editing therapies
- Moderna says non-inferiority endpoint not met for B strains in flu vaccine study